His comments have stemmed from the press release from Sanofi and Regeneron outlining their extensive Phase 3 program for their novel lipid lowering agent , REGN27, a PCSK9 inhibitor which is the most advanced agent in this highly competitive field.

FORBES: Is Big Pharma Utilizing Too Many Resources on Potential Blockbusters?

After Week 26, during the safety phase of the study, adjustments to concomitant lipid-lowering treatments were allowed.

FORBES: FDA Approves Lomitapide For Homozygous Familial Hypercholesterolemia